Plaque Psoriasis

Real-world data from patients with plaque psoriasis treated with guselkumab, who had previously been administered biologic agents is presented.

Results showed that apremilast met the primary end point achieving a statistically significant improvement in sPGA response at week 16 compared with placebo.

Real-world data from patients with plaque psoriasis treated with guselkumab, who had previously been administered biologic agents is presented.

The double-blind, placebo and active-controlled POETYK PSO-2 trial included 1022 patients 18 years of age and older with moderate to severe plaque psoriasis.

The correlation between physician-evaluated PASI and BSA involvement and patient-evaluated DLQI and PDI was evaluated in measuring psoriasis disease severity.

The efficacy of brodalumab for the treatment of nail psoriasis is assessed.

Time to, and predictors of, relapse in patients with psoriasis who responded to tildrakizumab then were assigned to placebo were reported.